Research Highlights

The Samuel Bronfman Department of Medicine's AIDS program ranked 14th in U.S. News & World Report Best Graduate School Rankings.

Ten members of the faculty of the Samuel Bronfman Department of Medicine are members of the Association of American Physicians.

Eighteen members of the faculty of the Samuel Bronfman Department of Medicine are members of The American Society for Clinical Investigators.

The Samuel Bronfman Department of Medicine is ranked 10th in the nation in the amount of funding received from the National Institutes of Health.

Mount Sinai researchers were the first to demonstrate that HIV is the direct cause of HIV associated nephropathy.

Mount Sinai is widely considered the leading center in the nation for both research and treatment of primary immunodeficiency, a term that describes more than 70 conditions in which part of the immune system doesn't function properly.

Mount Sinai researchers demonstrated that rising levels of follicle stimulating hormone (FSH) contribute to osteoporosis by stimulating osteoclasts to destroy bone tissue.

The Center for the Study of Health Beliefs and Behaviors is examining how patients beliefs about their disease and treatment influence their adherence to treatment regimens and therefore their quality of life.

Mount Sinai researchers developed of 5-azacytidine, the first drug approved by the FDA for this disorder.

Mount Sinai researchers demonstrated that a gel applied in the vagina provides protection from both the human immunodeficiency virus (HIV) and the herpes simplex virus.

Mount Sinai researchers were the first to recognize the importance of fibrosis as the final pathway leading from different inciting injuries to a common end result, cirrhosis.

Mount Sinai is one of only four referral centers in the country for amyloid diseases.

Mount Sinai is home to the largest sarcoidosis program in the world and is one of only ten Centers of Excellence chosen by the National Institutes of health to study the causes of sarcoidosis.

Mount Sinai researchers developed black-blood MRI, a non-invasive imaging technique that causes blood to appear dark while vessel walls appear bright, allowing cardiologists to identify thickening of the artery wall, an indication of otherwise undetectable vulnerable plaque.